Adar1 Capital Management, Llc Purchases 3,410 Shares of NextCure (NASDAQ:NXTC) Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc acquired 3,410 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was acquired at an average price of $5.00 per share, with a total value of $17,050.00. Following the acquisition, the insider owned 393,266 shares in the company, valued at approximately $1,966,330. This trade represents a 0.87% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, July 28th, Adar1 Capital Management, Llc bought 6,400 shares of NextCure stock. The shares were acquired at an average cost of $4.95 per share, for a total transaction of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc bought 7,798 shares of NextCure stock. The shares were acquired at an average price of $5.00 per share, with a total value of $38,990.00.

NextCure Stock Performance

Shares of NextCure stock traded down $0.40 during midday trading on Wednesday, reaching $5.02. 355,456 shares of the company’s stock traded hands, compared to its average volume of 939,730. The stock has a 50 day moving average of $3.76 and a 200-day moving average of $8.83. NextCure, Inc. has a 12 month low of $1.55 and a 12 month high of $15.74. The company has a market cap of $18.12 million, a PE ratio of -0.29 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating the consensus estimate of ($2.10) by $0.23. On average, equities analysts anticipate that NextCure, Inc. will post -7.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Cable Car Capital LP lifted its position in NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the period. Geode Capital Management LLC grew its holdings in NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after purchasing an additional 3,636 shares during the period. Renaissance Technologies LLC grew its holdings in NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after purchasing an additional 5,300 shares during the period. Exome Asset Management LLC bought a new position in shares of NextCure during the fourth quarter valued at approximately $2,341,000. Finally, AWM Investment Company Inc. purchased a new position in shares of NextCure during the fourth quarter valued at approximately $1,665,000. 42.65% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on NXTC shares. Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Weiss Ratings downgraded NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of NextCure in a research report on Wednesday, July 15th. Finally, Wall Street Zen cut NextCure from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, NextCure currently has a consensus rating of “Hold” and an average price target of $19.00.

NextCure Company Profile

NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.